Related Experiment Video
Updated: Jan 17, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and
Shota Yamamoto1, Takayuki Niitsu2, Kiyoharu Fukushima2
1Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Background:
Non-cystic fibrosis bronchiectasis is characterized by chronic respiratory symptoms and radiologic airway dilatation. Sustained neutrophilic inflammation is a key driver, prompting interest in antiinflammatory pharmacotherapy as a new treatment paradigm; however, comparisons among antiinflammatory agents are lacking.
Research Question:
What is the current profile concerning efficacy and safety of antiinflammatory therapies for bronchiectasis?
Study Design And Methods:
We performed a systematic review and network meta-analysis of randomized controlled trials that evaluated inhaled or oral antiinflammatory agents in adults with CT scan-confirmed bronchiectasis. PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, International Clinical Trials Registry Platform, and ClinicalTrials.gov were searched. Trials enrolling adults and using ≥ 4 weeks of treatment were eligible. The primary outcome was the rate of overall and severe exacerbations; secondary outcomes were quality of life, 6-minute walk distance, FEV1, and adverse events. The certainty of evidence was rated with Grading of Recommendations Assessment, Development, and Evaluation.
Results:
Thirty-one trials (N = 4,092) evaluating 8 antiinflammatory agents were included. Compared with placebo, macrolides (rate ratio [RR], 0.44; 95% CI, 0.35-0.56) and dipeptidyl-peptidase-1 (DPP-1) inhibitors (RR, 0.73; 95% CI, 0.60-0.88) reduced overall exacerbation frequency (both moderate certainty). DPP-1 inhibitors reduced the frequency of severe exacerbations (RR, 0.70; 95% CI, 0.54-0.89; moderate certainty). Macrolides showed a similar downward trend of severe exacerbations with very serious imprecision (RR, 0.54; 95% CI, 0.19-1.54; low certainty). Adverse events and treatment discontinuation rates were trivial or small for all interventions. In subgroup analyses, DPP-1 inhibitors remained effective irrespective of baseline long-term macrolide use (with macrolide: RR, 0.77; 95% CI, 0.60-0.99; without macrolide: RR, 0.77; 95% CI, 0.67-0.89). Among individual macrolides, azithromycin showed the greatest reduction in exacerbation frequency (RR, 0.37; 95% CI, 0.29-0.48).
Interpretation:
These findings support the use of DPP-1 inhibitors and macrolide antibiotics as antiinflammatory treatment options for bronchiectasis with frequent exacerbations.
Clinical Trial Registration:
PROSPERO; No.: CRD42024605694; URL: https://www.crd.york.ac.uk/prospero/.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...